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Abstract
Background: Several inflammatory response biomarkers, including lymphocyte-to-monocyte ratio (LMR),
neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) have been reported to predict survival
in various cancers. The aim of this study is to evaluate the clinical value of these biomarkers in patients undergoing
curative resection for esophageal cancer.
Methods: The LMR, NLR and PLR were calculated in 147 consecutive patients who underwent esophagectomy
between January 2006 and February 2015. We examined the prognostic significance of the LMR, NLR, and PLR in
both elderly and non-elderly patients. We evaluated the cancer-specific survival (CSS), with the cause of death
determined from the case notes or computerized records.
Results: Univariate analyses demonstrated that TNM pStage (p < 0.0001), tumor size (p = 0.0014), operation time
(p = 0.0209), low LMR (p = 0.0008), and high PLR (p = 0.0232) were significant risk factors for poor prognosis.
Meanwhile, TNM pStage (p < 0.0001) and low LMR (p = 0.0129) were found to be independently associated with
poor prognosis via multivariate analysis.
In non-elderly patients, univariate analyses demonstrated that TNM pStage (p < 0.0001), tumor size (p = 0.0001),
operation time (p = 0.0374), LMR (p < 0.0001), and PLR (p = 0.0189) were significantly associated with a poorer
prognosis. Multivariate analysis demonstrated that TNM pStage (p = 0.001) and LMR (p = 0.0007) were independent
risk factors for a poorer prognosis.
In elderly patients, univariate analysis demonstrated that that TNM pStage (p = 0.0023) was the only significant risk
factor for a poor prognosis.
Conclusions: LMR was associated with cancer-specific survival (CSS) of esophageal cancer patients after curative
esophagectomy. In particular, a low LMR was a significant and independent predictor of poor survival in non-
elderly patients. The LMR was convenient, cost effective, and readily available, and could thus act as markers of
survival in esophageal cancer.
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Background
It is now widely recognized that host-related factors, such as
performance status, weight loss, smoking, and comorbidity,
as well as the biological properties of individual tumors, play
an important role in cancer outcomes [1]. Recent studies
have shown that preoperative inflammation-based prognos-
tic scores have a significant predictive and prognostic value
in various types of cancers [2–4]. A systemic inflammatory
response has been reported to be associated with tumor
development, apoptosis inhibition, and angiogenesis pro-
motion, thus resulting in tumor progression and metastasis
[5, 6]. Furthermore, significant relationships between
patient survival and the lymphocyte-to-monocyte ratio
(LMR), neutrophil-to-lymphocyte ratio (NLR), and platelet-
to-lymphocyte ratio (PLR) have been documented in vari-
ous cancers [7–9]. However, only a few studies have evalu-
ated the utility of inflammation-based scores for assessing
the prognosis of patients with esophageal cancer.
The aim of the present study was to evaluate whether
the LMR, NLR, and PLR have prognostic values inde-
pendent of conventional clinicopathological features in
patients undergoing a potentially curative resection for
esophageal cancer. Additionally, this study stratified pa-
tients into two age groups, elderly patients aged 70 years
or older and patients aged under 70 years, because
esophageal cancer occurs predominantly in elderly
people and age-specific prognostic factors in patients
with esophageal cancer have not yet been identified.
Methods
Patients
We retrospectively reviewed a database of medical re-
cords from 147 consecutive patients who underwent
curative esophagectomy with R0 resection for histologi-
cally verified esophageal squamous cell carcinoma be-
tween January 2006 and February 2015 at Shimane
University Faculty of Medicine. R0 resection was defined
as a complete resection without any microscopic resec-
tion margin involvement. Video-assisted or thoraco-
scopic subtotal esophagectomy with three-field lymph
node dissection was performed in all patients, followed
by laparoscopic gastric surgery with an elevation of the
gastric conduit to the neck via the posterior mediastinal
or a retrosternal approach with an end-to-end anasto-
mosis of the remnant cervical esophagus and fundus of
the gastric conduit. The patients’ clinical characteristics,
laboratory data, treatment, and pathological data were
obtained from medical records. Preoperatively, no pa-
tients had clinical signs of infection or other systemic in-
flammatory conditions. Based on the age distribution of
the patients, they were subdivided into two groups in
this study: patients <70 years (non-elderly group) and
patients ≥70 years (elderly group). We evaluated cancer-
specific survival (CSS), with the cause of death deter-
mined from case notes or computerized records.
This retrospective study was approved with the ethical
board of Shimane University Faculty of Medicine, and
was conducted in accordance with the Declaration of
Helsinki. Informed consent was obtained from all indi-
vidual participants included in the study.
Blood sample analysis
Data on preoperative complete blood cell (CBC) counts
were retrospectively extracted from patient medical re-
cords. Only patients with available preoperative CBC
count and blood differential data were included in the
study. All white blood cell and differential counts were ob-
tained within 1 week prior to surgery. CBC was measured
using ethylenediaminetetraacetic acid-treated blood, and
analyzed using an automated hematology analyzer XE-
5000 (SYSMEX K1000 hematology analyzer; Medical Elec-
tronics, Kobe, Japan). Absolute counts of lymphocytes,
monocytes, and platelets were obtained from CBC tests.
LMR, NLR, and PLR evaluations
The LMR was calculated from a routinely performed
preoperative blood cell count as the absolute lymphocyte
count divided by the absolute monocyte count. White
blood cell count data were analyzed in the general rou-
tine laboratory of our hospital. The NLR was calculated
as a simple ratio between the absolute neutrophil and
absolute lymphocyte counts, as provided by the differen-
tial white blood cell count. The PLR was calculated from
the differential count by dividing the absolute platelet
count by the absolute lymphocyte count.
TNM stage
The pathological classification of the primary tumor, de-
gree of lymph node involvement, and presence of organ
metastasis were determined according to the TNM clas-
sification system [10].
Statistical analysis
Means and standard deviations were calculated, and dif-
ferences between groups were evaluated using a Student’s
t-test. Differences between categories of each clinicopath-
ological feature were analyzed using a Chi-square (χ2) test.
We determined the optimal cut-off levels of the LMR,
NLR, and PLR by applying receiver operating curve
(ROC) analysis. Regarding LMR, the area under curve
(AUC) was 0.69 for CSS. A value of 4.0 was chosen as
the cut-off level for LMR for CSS as associated with a
high sensitivity and specificity for CSS (62.5 and 71.3 %,
respectively). Regarding NLR, the AUC was 0.58 for
CSS. A value of 1.6 was chosen as the cut-off level for
NLR for CSS as associated with a sensitivity and specifi-
city for CSS (57.5 and 66.3 %, respectively). Regarding
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PLR, the AUC was 0.65 for CSS. A value of 147 was
chosen as the cut-off level for PLR for CSS as associated
with a high sensitivity and specificity for CSS (59.6 and
68.4 %, respectively). The patients with LMR, NLR,
and PLR greater than these cutoff values were consid-
ered to have high LMR, NLR, and PLR, respectively;
the remaining patients were considered to have low
LMR, low NLR, and low PLR. CSS was calculated
using Kaplan–Meier analysis, and differences between
the groups were assessed by a log-rank test. Addition-
ally, prognostic factors associated with decreased sur-
vival rates were determined using Cox regression
analysis.
Univariate analyses were performed to determine
which variables were associated with CSS. Variables with
a p-value <0.05 in univariate analysis were subjected to
multivariate logistic regression analysis. The potential
prognostic factors for esophageal cancer were as follows:
age (<70 vs. ≥70 years); sex (female vs. male); pStage (I,
II vs. III); tumor size (<3 cm vs. ≥3 cm); operation time
(<600 vs. ≥600 min); intraoperative blood loss (<5 00 mL
vs. ≥500 mL); LMR (≥4 vs. <4); NLR (≥1.6 vs. <1.6); PLR
(<147 vs. ≥147); weight loss (No vs. Yes: Weight loss
was defined as more than 5 % decreasing in the body
weight in the last 3 months preceding operation); and
serum squamous cell carcinoma (SCC) antigen value
(<1.5 vs. ≥1.5). Medical records were retrospectively
reviewed to examine these factors.
All statistical analyses were performed using the statis-
tical software JMP (version 11 for Windows; SAS Institute,
Cary, NC, USA), and p-values <0.05 were considered
statistically significant.
Results
Relationships between LMR, NLR, PLR, and
clinicopathological features in patients with esophageal
cancer
The relationships between LMR, NLR, PLR, and clinico-
pathological features in 147 patients with esophageal
cancer are shown in Table 1.
Significant correlations were observed between the
LMR and factors such as lymphocyte count (p < 0.0001),
monocyte count (p < 0.0001), tumor size (p = 0.014),
tumor depth (p = 0.0007), and TNM pStage (p = 0.0002).
The NLR was significantly correlated with neutrophil
count (p < 0.0001), lymphocyte count (p < 0.0001), and
tumor depth (p = 0.002). Furthermore, significant corre-
lations were observed between the PLR and lymphocyte
count (p < 0.0001), platelet count (p < 0.0001), and tumor
location (p = 0.042). It is notable that a low LMR was
significantly correlated with more advanced TNM
pStage, while the NLR and PLR showed no significant
associations with TNM pStage.
Prognostic factors for CSS in overall patients with
esophageal cancer
Univariate analyses demonstrated that TNM pStage (p <
0.0001), tumor size (p= 0.0014), operation time (p= 0.0209),
low LMR (p= 0.0008), and high PLR (p= 0.0232) were sig-
nificant risk factors for poor prognosis (Table 2).
TNM pStage (HR, 4.190; 95 % CI, 2.146–8.562; p <
0.0001) and low LMR (HR, 2.372; 95 % CI, 1.198–4.840;
p = 0.0129) were found to be independently associated
with poor prognosis via multivariate analysis (Table 2).
Relationships between LMR, NLR, PLR, and
clinicopathological features in non-elderly patients with
esophageal cancer
The relationships between LMR, NLR, PLR, and clinico-
pathological features in non-elderly patients (younger than
70 years) are shown in Table 3. Significant correlations were
observed between the LMR and such factors as lymphocyte
count (p < 0.0001), monocyte count (p < 0.0001), tumor
location (p = 0.0169), tumor size (p = 0.0309), tumor depth
(p = 0.0093), and TNM pStage (p = 0.0003). The NLR was
significantly correlated with neutrophil count (p < 0.0001),
lymphocyte count (p < 0.0001), tumor size (p = 0.0452),
tumor depth (p = 0.0018), and TNM pStage (p = 0.0032).
Furthermore, significant correlations were observed be-
tween the PLR and lymphocyte count (p < 0.0001) as well
as platelet count (p < 0.0001).
Prognostic factors for CSS in non-elderly patients with
esophageal cancer
In non-elderly patients, univariate analyses demonstrated
that TNM pStage (p < 0.0001), tumor size (p = 0.0001),
operation time (p = 0.0374), LMR (p < 0.0001), and PLR
(p = 0.0189) were significantly associated with a poorer
prognosis. Multivariate analysis demonstrated that TNM
pStage (HR, 4.009; 95 % CI, 1.731–10.162; p = 0.001) and
LMR (HR, 4.553; 95 % CI, 1.856–12.516; p = 0.0007) were
independent risk factors for a poorer prognosis (Table 4).
Relationships between LMR, NLR, PLR, and
clinicopathological features in elderly patients with
esophageal cancer
The relationships between LMR, NLR, PLR, and clinico-
pathological features in elderly patients (70 years or older)
are shown in Tables 5. Significant correlations were ob-
served between the LMR and such factors as lymphocyte
count (p < 0.0001), monocyte count (p = 0.0001), and
serum SCC antigen (p = 0.0342). The NLR was signifi-
cantly correlated with factors such as WBC (p = 0.0146),
age (p = 0.012), lymphocyte count (p < 0.0001), and neu-
trophil count (p = 0.0009). Furthermore, significant corre-
lations were observed between the PLR and lymphocyte
count (p < 0.0001) as well as platelet count (p = 0.0009).
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Age (years) 65.8 ± 7.4 65.7 ± 8.2 0.934 65.4 ± 8.0 65.9 ± 7.9 0.72 66.8 ± 8.1 64.6 ± 7.6 0.097
Gender 0.052 0.163 0.562
Male 132 61 71 31 101 72 60
Female 15 3 12 6 9 7 8
WBC 6082.2 ± 2153.2 5844.3 ± 1788.2 0.466 5284.1 ± 1667.3 6171.2 ± 1996.5 0.016 6190.9 ± 1723.0 5665.6 ± 2167.2 0.104
Neutrophil 3944.7 ± 1804.6 3412.8 ± 1470.4 0.051 2491.0 ± 948.3 4032.3 ± 1643.7 <0.0001 3509.3 ± 1300.5 3801.3 ± 1960.9 0.283
Lymphocyte 1322.0 ± 546.4 1942.5 ± 584.5 <0.0001 2187.6 ± 658.6 1499.0 ± 541.8 <0.0001 2029.2 ± 586.3 1257.7 ± 426.2 <0.0001
Monocyte 546.8 ± 211.3 328.7 ± 111.1 <0.0001 379.0 ± 161.3 438.7 ± 203.3 0.1074 418.2 ± 171.3 430.0 ± 220.2 0.714
Platelet 236.6 ± 79.2 226.9 ± 66.2 0.42 231.0 ± 76.9 231.2 ± 70.7 0.987 203.5 ± 49.2 263.2 ± 80.9 <0.0001
Location of tumor 0.09 0.313 0.042
Ce 6 5 1 1 5 0 6
Ut 8 4 4 0 8 5 3
Mt 65 29 36 20 45 32 33
Lt 52 23 29 11 41 31 21
Ae 16 3 13 5 11 11 5
Tumor size (mm) 4.9 ± 1.9 3.9 ± 2.7 0.014 3.8 ± 2.8 4.5 ± 2.3 0.134 4.0 ± 2.5 4.8 ± 2.3 0.056
Depth of tumor 0.0007 0.002 0.06
T1a-1b 66 20 46 18 48 40 26
2 12 2 10 8 4 9 3
3 56 33 23 8 48 26 30
4a-4b 13 9 4 3 10 4 9
Lymph node metastasis 0.2732 0.1532 0.0639
N0 79 30 49 22 57 43 36
N1 42 19 23 12 30 25 17
N2 12 8 4 3 9 8 4
N3 14 7 7 0 14 3 11
Pathological stage 0.0002 0.1338 0.3497
1a-1b 59 14 45 20 39 36 23
2a-2b 33 21 12 6 27 16 17
3a-3c 55 29 26 11 44 27 28
Operation time (min) 644.8 ± 162.2 663.5 ± 159.2 0.4843 655.9 ± 177.2 655.2 ± 155.0 0.9798 676.5 ± 149.0 630.8 ± 170.2 0.0845
Intraoperative blood loss (ml) 751.8 ± 622.8 581.6 ± 633.4 0.1059 568.8 ± 511.1 684.9 ± 667.8 0.3359 598.5 ± 633.1 722.2 ± 629.7 0.2384
SCC antigen 1.19 ± 1.06 1.12 ± 1.12 0.7208 1.04 ± 1.12 1.19 ± 1.08 0.7643 1.05 ± 0.91 1.27 ± 1.26 0.8858












Prognostic factors for CSS in elderly patients with
esophageal cancer
In elderly patients, univariate analysis demonstrated that
that TNM pStage (p = 0.0023) was the only significant
risk factor for a poor prognosis (Table 6).
Postoperative CSS based on LMR, NLR, and PLR in all
patients with esophageal cancer
Patients with a low LMR had a significantly poorer prog-
nosis in terms of CSS than those with a high LMR (p =
0.0006). In contrast, patients with a high PLR had a sig-
nificantly poorer prognosis than those with a low PLR
(p = 0.0169), whereas no significant differences in CSS
were observed between patients with a low or high NLR
(p = 0.3214; Fig. 1a-c).
Postoperative CSS based on LMR, NLR, and PLR in
non-elderly patients with esophageal cancer
Patients with a low LMR had a significantly poorer prog-
nosis in terms of CSS than those with a high LMR (p <
0.0001). In contrast, patients with a high PLR had a sig-
nificantly poorer prognosis than those with a low PLR
(p = 0.0172), whereas no significant differences in CSS
were observed between patients with a low or high NLR
(p = 0.3714; Fig. 2a-c).
Postoperative CSS based on LMR, NLR, and PLR in elderly
patients with esophageal cancer
In the elderly group, no significant differences in CSS
were observed between patients with either low or high
LMR (p = 0.4700), NLR (p = 0.9698), or PLR (p = 0.5386;
Fig. 3a-c).
Discussion
Pathological features, including tumor stage, nodal sta-
tus, and resection margin, are considered important in
determining cancer patient survival [11]. However, it is
now clear that cancer survival is not solely determined
by tumor pathology; indeed, recent studies have shown
that preoperative inflammation-based prognostic scores
can predict the overall survival of patients with various
types of cancers [2–4]. In the present study, we retro-
spectively analyzed the clinical data of patients undergo-
ing a potentially curative resection for esophageal cancer
to determine whether the LMR, NLR, and PLR have
prognostic values according to each TNM pStage. The
results demonstrated that the LMR can be used as a
novel predictor of postoperative CSS in patients with
esophageal cancer after curative esophagectomy. Add-
itionally, univariate analyses revealed that a low LMR
was a significant risk factor for poor prognosis in stage
III patients, whereas no prognostic factor was detected
in patients with stage I or II cancer.
Interleukin-6 (IL-6) is a multifunctional inflammatory
cytokine that triggers the proliferation and differentiation
of a variety of cell types, including immune competent
cells and hematopoietic cells. IL-6 induces not only neu-
trophil proliferation, but also the differentiation of mega-
karyocytes to platelets, and these events are similar to
those underlying the systemic inflammatory response
(SIR) [12, 13]. Theoretically, dynamic changes in the SIR
resulting from tumor-host interactions are best estimated
by directly measuring the serum IL-6 level. However, rou-
tine measurement of IL-6 in cancer patients in the clinical
setting is expensive and inconvenient. On the other hand,
the LMR, NLR, and PLR are based on blood cell compo-
nents whose levels are regulated by cytokines, most not-
ably, IL-6; these blood cell components proliferate and
differentiate immediately after inflammatory cytokine re-
lease [14]. Moreover, measurement of the LMR, NLR, and
PLR is easy, convenient, and cost-effective and therefore
can be performed routinely.
In this study, we examined the prognostic significance
of the LMR, NLR, and PLR in both elderly and non-






HR 95 % CI p value HR 95 % CI p value
Gender 15/132 (female/male) 0.942 0.406–2.740 0.9007
Age 46/101 (70</≥70) 1.427 0.742–2.639 0.2771
pStage 92/55 (1,2/3) 4.876 2.625–9.420 <0.0001 4.19 2.146–8.562 <0.0001
Tumor size 45/102 (3</≥3) 3.405 1.548–8.981 0.0014 1.433 0.580–4.056 0.4493
Operation time 99/48 (600</≥600) 2.041 1.116–3.741 0.0209 1.425 0.757–2.681 0.2699
Intraoperative blood loss 72/75 (500</≥500) 1.321 0.723–2.463 0.3663
LMR 83/64 (≥4.0/4.0<) 2.829 1.537–5.378 0.0008 2.372 1.198–4.840 0.0129
NLR 37/110 (≥1.6/1.6<) 1.469 0.753–2.734 0.2494
PLR 79/68 (147</≥147) 2.013 1.100–3.783 0.0232 1.12 0.611–2.404 0.5999
SCC antigen 109/38 (1.5</≥1.5) 1.3 0.603–2.564 0.4842
LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, PLR platelet lymphocyte ratio, SCC squamous cell carcinoma, HR hazard ratio, CI confidence interval
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Age (years) 61.9 ± 5.2 61.6 ± 5.6 0.7778 61.1 ± 5.8 61.9 ± 5.3 0.7249 62.4 ± 5.2 60.8 ± 5.5 0.1294
Gender 0.1283 0.2392 0.1171
Male 91 41 50 21 70 51 40
Female 10 2 8 4 6 3 7
WBC 6261.2 ± 2234.8 5951.4 ± 1747.8 0.7819 5654.4 ± 1725.4 6224.3 ± 2028.8 0.2101 6242.2 ± 1660.6 5900.6 ± 287.0 0.3863
Neutrophil 4020.2 ± 1757.4 3506.3 ± 1522.4 0.9402 2645.3 ± 978.7 4080.3 ± 1659.8 <0.0001 3481.2 ± 1252.0 4005.4 ± 1969.1 0.109
Lymphocyte 1352.8 ± 621.1 1964.2 ± 584.6 <0.0001 2362.7 ± 651.4 1487.2 ± 520.4 <0.0001 2068.7 ± 601.1 1284.7 ± 473.7 <0.0001
Monocyte 574.3 ± 223.8 336.1 ± 109.6 <0.0001 395.8 ± 163.2 451.3 ± 215.8 0.2417 438.1 ± 172.2 436.9 ± 238.6 0.9756
Platelet 230.1 ± 76.1 233.0 ± 70.2 0.8422 215.2 ± 64.4 237.2 ± 74.5 0.9051 205.7 ± 47.3 261.7 ± 84.3 <0.0001
Location of tumor 0.0169 0.5489 0.1445
Ce 4 4 0 0 4 0 4
Ut 4 3 1 0 4 3 1
Mt 49 23 26 14 35 24 25
Lt 31 11 20 8 23 19 12
Ae 13 2 11 3 10 8 5
Tumor size (mm) 4.9 ± 2.1 3.9 ± 2.8 0.0309 3.4 ± 2.7 4.6 ± 2.5 0.0452 4.0 ± 2.8 4.7 ± 2.2 0.2116
Depth of tumor 0.0093 0.0018 0.0943
T1a-1b 44 12 32 13 31 29 15
2 6 1 5 5 1 4 2
3 40 23 17 5 35 17 23
4a-4b 11 7 4 2 9 4 7
Lymph node metastasis 0.5691 0.1307 0.3183
N0 56 22 34 18 38 32 24
N1 28 13 15 6 22 16 12
N2 6 4 2 1 5 3 3
N3 11 4 7 0 11 3 8
Pathological stage 0.0003 0.0032 0.1024
1a-1b 41 9 32 17 24 27 14
2a-2b 20 15 5 1 19 8 12
3a-3c 40 19 21 7 33 19 21
Operation time (min) 617.8 ± 142.7 666.4 ± 148.0 0.101 643.33 ± 151.1 646.5 ± 146.8 0.9246 680.2 ± 147.9 606.0 ± 137.2 0.107
Intraoperative blood loss (ml) 727.9 ± 578.1 538.5 ± 523.1 0.0543 616.4 ± 567.6 620.1 ± 551.2 0.9772 563.0 ± 531.4 683.7 ± 574.5 0.2753
SCC antigen 1.01 ± 0.76 1.20 ± 1.26 0.3828 1.11 ± 1.26 1.11 ± 1.02 0.9667 1.04 ± 0.97 1.20 ± 1.19 0.465












elderly patients undergoing thoracoscopic esophagec-
tomy for esophageal cancer. Esophageal cancer is the
eighth most common cancer and the sixth most com-
mon cause of cancer deaths worldwide [15]. It occurs
predominantly in elderly people, and the average age at
the time of diagnosis continues to rise, with a peak inci-
dence between 70 and 75 years of age [16]. Because age-
specific prognostic factors in patients with esophageal
cancer have not yet been described, we divided patients
into two age groups in order to determine the age-
specific prognostic values of the LMR, NLR, and PLR.
The reason we chose a cut-off value of 70 years is be-
cause “elderly” is typically defined as a patient aged over
70 years in a plurality of studies on elderly patients with
esophageal cancer [17–19].
Platelets are a key element linking the processes of
hemostasis, inflammation, and tissue repair. Previous
studies have shown that proinflammatory mediators
stimulate megakaryocyte proliferation and are respon-
sible for platelet production [20, 21]. Consequently,
platelet activation causes angiogenic growth factor re-
lease as well as platelet adherence to tumor microvessels
and extravasation via increased vascular permeability;
this process leads to platelet activation [22, 23]. Lympho-
cytes can cause systemic inflammation by releasing nu-
merous inhibitory immunologic mediators, particularly
interleukin-10 and transforming growth factor-ß, which
may consequently cause suppression of antitumor im-
munity via decreased regulatory T cell levels [6]. Accord-
ingly, there is increasing evidence that lymphocytes are
essential for antitumor immune reactions owing to sev-
eral mechanisms, including the ability to enhance tumor
cell apoptosis, inhibition of tumor cell proliferation, and
promotion of metastasis [24]. Neutrophils are known to
not only produce angiogenic cytokines, but have also
been shown to generate matrix metalloproteinase-9,
which induces an angiogenic state in cancer cells [25].
Based on such inflammatory responses, systemic in-
flammatory markers such as the LMR, NLR, and PLR
have been shown to predict mortality and recurrence in
a variety of cancers, but their role in esophageal cancer
remains controversial [7, 20, 26].
We revealed that a low LMR in patients with esophageal
cancer was significantly correlated with more advanced
TNM pStage (p = 0.0002), but a low LMR was found to be
independently associated with poor prognosis via multi-
variate analysis (HR, 2.372; p = 0.0129), as determined by
Kaplan-Meier analysis and a log-rank test (p = 0.0006). A
definitive explanation for our findings remains speculative.
Monocytes are known to promote tumorigenesis and
angiogenesis through local immune suppression and
stimulation of tumor neovasculogenesis [25]. Moreover,
tumor-associated macrophages developing from mono-
nuclear cell lineages have been demonstrated to be able to
inhibit cancer progression and spread of metastatic tu-
mors [27, 28]. This could explain why an elevated mono-
cyte count confers poor clinical outcomes in various types
of cancers [29]. A poor prognosis was observed in patients
with a low LMR in this study, which is reasonable because
both lymphopenia and monocytosis induce immune sup-
pression, as mentioned above. Moreover, the results of
subgroup analysis revealed that the preoperative LMR was
the most significant prognostic factor in non-elderly pa-
tients (HR, 4.553; p = 0.0007), as determined by Kaplan-
Meier analysis and a log-rank test (p < 0.0001), but not in
elderly patients. The present study may have failed to
demonstrate a prognostic significance of the LMR in eld-
erly patients because these patients were more likely to
have advanced age-related conditions that cause immune
suppression. Further investigations are required to eluci-
date the precise mechanisms that affect the prognosis of
esophageal cancer patients.
Changes in platelet count and platelet function have
been identified as part of a paraneoplastic syndrome in






HR 95 % CI p value HR 95 % CI p value
Gender 10/91 (female/male) 0.608 0.233–20.78 0.388
pStage 61/40 (1,2/3) 5.022 2.321–11.715 <0.0001 4.009 1.731–10.162 0.001
Tumor size 34/67 (3</≥3) 8.34 2.491–51.782 0.0001 3.115 0.788–20.674 0.1114
Operation time 67/34 (600</≥600) 2.219 1.048–4.752 0.0374 1.109 0.490–2.540 0.803
Intraoperative blood loss 49/52 (500</≥500) 1.53 0.723–3.373 0.2679
LMR 58/43 (≥4/4<) 5.076 2.259–12.909 <0.0001 4.553 1.856–12.516 0.0007
NLR 25/76 (≥1.6/1.6<) 1.593 0.656–4.750 0.322
PLR 54/47 (147</≥147) 2.475 1.160–5.592 0.0189 1.163 0.499–2.845 0.5999
SCC antigen 76/25 (1.5</≥1.5) 0.915 0.305–2.244 0.857
LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, PLR platelet lymphocyte ratio, SCC squamous cell carcinoma, HR hazard ratio, CI confidence interval
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Age (years) 74.0 ± 3.8 75.4 ± 4.4 0.8781 74.3 ± 3.0 75.0 ± 4.5 0.6094 76.2 ± 4.3 73.1 ± 3.3 0.012
Gender 0.2226 0.453 0.2226
Male 41 20 21 10 31 21 20
Female 5 1 4 2 3 4 1
WBC 5715.7 ± 1976.4 5596.0 ± 1891.6 0.835 4512.5 ± 1281.2 6052.4 ± 1946.8 0.0146 6080.0 ± 1881.6 5139.5 ± 1858.8 0.0966
Neutrophil 3790.0 ± 1932.6 3195.8 ± 1346.0 0.2271 2169.4 ± 828.4 3925.1 ± 1626.7 0.0009 3570.0 ± 1424.7 3344.5 ± 1909.4 0.649
Lymphocyte 1258.9 ± 352.0 1892.1 ± 593.0 <0.0001 1822.8 ± 528.1 1525.4 ± 594.0 0.1327 1943.9 ± 555.2 1197.2 ± 294.4 <0.0001
Monocyte 490.2 ± 174.3 311.6 ± 115.0 0.0001 344.1 ± 158.3 410.5 ± 171.8 0.2469 375.1 ± 164.4 414.7 ± 176.4 0.4351
Platelet 250.0 ± 85.7 212.8 ± 54.3 0.0805 263.8 ± 92.6 217.8 ± 60.4 0.0563 198.8 ± 53.8 266.6 ± 74.7 0.0009
Location of tumor 0.6568 0.1274 0.2753
Ce 2 1 1 1 1 0 2
Ut 4 1 3 0 4 2 2
Mt 16 6 10 6 10 8 8
Lt 21 12 9 3 18 12 9
Ae 3 1 2 2 1 3 0
Tumor size (mm) 4.9 ± 1.5 3.9 ± 2.5 0.0987 4.6 ± 3.2 4.3 ± 1.7 0.6459 3.9 ± 1.8 4.9 ± 2.4 0.0987
Depth of tumor 0.0716 0.3997 0.2032
T1a-1b 22 8 14 5 17 11 11
2 6 1 5 3 3 5 1
3 16 10 6 3 13 9 7
4a-4b 2 2 0 1 1 0 2
Lymph node metastasis 0.1229 0.2441 0.0875
N0 23 8 15 4 19 11 12
N1 14 6 8 6 8 9 5
N2 6 4 2 2 4 5 1
N3 3 3 0 0 3 0 3
Pathological stage 0.0825 0.3939 0.8129
1a-1b 18 5 13 3 15 9 9
2a-2b 13 6 7 5 8 8 5
3a-3c 15 10 5 4 11 8 7
Operation time (min) 700.0 ± 187.8 656.8 ± 185.7 0.4385 682.3 ± 227.8 674.5 ± 172.6 0.9021 668.5 ± 154.0 686.2 ± 221.6 0.7515
Intraoperative blood loss (ml) 800.7 ± 718.7 681.5 ± 840.3 0.3057 469.8 ± 368.8 829.9 ± 866.8 0.1723 675.2 ± 818.5 808.2 ± 746.9 0.2854
SCC antigen 1.56 ± 1.44 0.96 ± 0.68 0.0342 0.90 ± 0.80 1.35 ± 1.21 0.2379 1.07 ± 0.78 1.42 ± 1.43 0.2961












many cancers [30], and a high platelet count was found
to be closely associated with TNM pStage, metastasis, as
well as a high risk of recurrence in many types of cancer
[31, 32]. Consequently, the PLR may act as a marker of
the balance between host inflammatory and immune re-
sponses. However, to the best of our knowledge, the re-
lationship between the PLR and esophageal cancer has
not yet been described. We therefore focused on the
PLR and CSS in esophageal cancer patients. Although
univariate analysis demonstrated that the PLR was a sig-
nificant risk factor for poorer CSS, as determined by
Kaplan-Meier analysis and a log-rank test (p = 0.0169),
multivariate analysis failed to confirm that the PLR was
a significant predictor of CSS. Similarly, in non-elderly
patients, univariate analysis demonstrated that the PLR
was a significant risk factor for poorer CSS (p = 0.0172),
but this significance was lost when analysis was confined
to elderly patients. Recent studies have demonstrated
that termed combination of platelet count and mean
platelet volume is a predictor for postoperative survival
in esophageal cancer patients [33]. Further studies are
necessary to examine the role of these inflammatory bio-
markers in various types of cancers.
The NLR has been reported to be highly promising in
stratifying the outcome in large cohorts of patients with
cancer [34, 35]. The relationship between the NLR and






HR 95 % CI p value HR 95 % CI p value
Gender 5/41 (female/male) 3.114 0.611–56.892 0.201
pStage 31/15 (1,2/3) 5.22 1.824–16.080 0.0023 5.22 1.824–16.080 0.0023
Tumor size 11/35 (3</≥3) 0.976 0.333–3.529 0.9666
Operation time 32/14 (600</≥600) 1.761 0.615–4.929 0.2822
Intraoperative blood loss 23/23 (500</≥500) 0.981 0.349–2.820 0.9707
LMR 25/21 (≥4/4<) 1.118 0.368–3.175 0.837
NLR 12/34 (≥1.6/1.6<) 0.853 0.464–1.535 0.718
PLR 25/21 (147</≥147) 1.3 0.464–3.712 0.616
SCC antigen 33/13 (1.5</≥1.5) 2.261 0.689–6.565 0.167
LMR lymphocyte to monocyte ratio, NLR neutrophil to lymphocyte ratio, PLR platelet lymphocyte ratio, SCC squamous cell carcinoma, HR hazard ratio, CI, confidence interval
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Fig. 1 Kaplan-Meier survival curves showing CSS after curative esophagectomy in overall patients with esophageal cancer. a LMR. b NLR. c PLR
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prognosis is probably complex and remains unclear. Re-
cently, many studies have shown that a high NLR may in-
dicate an impaired host immune response to the tumor
[36]. In this study, the NLR did not affect the prognosis of
esophageal cancer patients following curative resection,
which may be due to the small retrospective sample size
and short follow-up duration of the study. However, other
components of the systemic inflammatory response, in-
cluding cytokines and chemokines, have proven prognos-








Fig. 3 Kaplan-Meier survival curves showing CSS after curative esophagectomy in elderly patients with esophageal cancer. a LMR. b NLR. c PLR
Hirahara et al. BMC Surgery  (2016) 16:66 Page 10 of 12
There were several potential limitations that warrant
consideration in our study, which include single-
institution retrospective analysis, short follow-up periods,
and a small sample size, especially elderly patients.
Furthermore, we excluded patients who had received ad-
juvant chemotherapy and/or radiotherapy, which may
have influenced our analysis. Thus, large, prospective, ran-
domized controlled trials are needed to confirm these pre-
liminary results. In addition, the amount of weight loss are
well-known prognostic factors for various types of
cancers. Minimal weight loss and a good performance sta-
tus are considered favorable prognostic factors. Needless
to say significant weight loss may impact bone marrow
function as well as the patient’s ability to mount a host-
tumor response. But we could not reveal that weight loss
were proven to be independent prognostic factors in
esophageal cancer, because our study is retrospective ana-
lysis, and data about the weight loss are insufficient.
Conclusion
In conclusion, our study demonstrated that the LMR and
PLR were associated with CSS of esophageal cancer pa-
tients after curative esophagectomy. Moreover, the results
of subgroup analysis revealed that the preoperative LMR
and PLR were the most significant prognostic factors in
non-elderly patients, as determined by Kaplan-Meier ana-
lyses and log-rank tests. In particular, a low LMR was a
significant and independent predictor of poor survival. In
non-elderly patients, a low LMR was also an independent
risk factor for a poorer prognosis. The LMR and PLR are
convenient, cost effective, and readily available as a part of
routine complete blood counts, and could thus act as
markers of survival in this malignancy.
Abbreviations
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LMR: Lymphocyte to monocyte ratio; NLR: Neutrophil to lymphocyte ratio;
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